Upstream Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $265.6M
- Price
- $4.85
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.77%
- Volume
- 1.0M
About
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Quick stats
Shares outstanding54.8M
Computed float37.9M
Float / shares69.2%
Cash runway (months)17.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002022626
Websitehttps://upstreambio.com
AI Summary
AI-generated1/15
majorbullishclinical trial
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
Upstream Bio presented Phase 2 VALIANT results at the ERS Congress 2026, showing verekitug dosed at 100 mg every 12 weeks reduced the annualized asthma exacerbation rate by 56% versus placebo (p<0.001) in adults with severe asthma.
The full dataset showed statistically significant improvements in lung function (FEV1), exhaled nitric oxide (FeNO), and ACQ-6 symptom scores at week 24, with benefit visible as early as week 2, and a safety profile consistent with prior studies. VALIANT enrolled 478 patients regardless of baseline eosinophil or type-2 biomarker levels, and more than 500 participants have now been treated with verekitug to date.
The company reaffirmed plans to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027 using a 400 mg every-12-week regimen, while the VALOUR long-term extension study completed enrollment in March 2026 with over 90% retention and reports data in the second half of 2027.
Red flags
- Clinical-stage issuer with no revenue; forward-looking statements explicitly flag the need for substantial additional funds to complete development — future dilution risk
- Phase 3 start remains subject to additional FDA interactions on the sufficiency of the Phase 3 development plans
- Topline VALIANT results were previously reported; this is the fuller congress presentation, not a new readout